bluebird bio (BLUE) Confirms FDA Approval of ZYNTEGLO Gene Therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
bluebird bio (BLUE) Falls to Low, Down 18%
August 18, 2022 10:38 AM EDTbluebird bio (NASDAQ: BLUE) Falls to Low, Down 18%
... MoreUPDATE: bluebird bio's (BLUE) Zynteglo Gets FDA Approval - List Price In-Line Says Analyst
August 17, 2022 4:22 PM EDT(Updated - August 17, 2022 4:23 PM EDT)
bluebird bio's (NASDAQ: BLUE) cell-based gene therapy, Zynteglo, has been approved for the treatment of adult and pediatric patients with beta-thalassemia by the U.S. Food and Drug Administration, it was announced Wednesday.
Beta-thalassemia is a type of inherited blood disorder that causes a reduction of normal hemoglobin and red blood cells in the blood. Zynteglo is the first cell-based gene therapy to treat the blood disorder.
Zynteglo is a one-time gene therapy product administered as a single dose. Its safety and effectiveness were established in... More
bluebird bio (BLUE) Resumes Trading, Up 20%
August 17, 2022 2:30 PM EDTbluebird bio (NASDAQ: BLUE) Resumes Trading, Up 20%
... Morebluebird bio (BLUE) to Resume Trading at 2:30 p.m.
August 17, 2022 2:10 PM EDTbluebird bio (NASDAQ: BLUE) to Resume Trading at 2:30 p.m.
... Morebluebird bio (BLUE) to Charge $2.8M for Fda-Cleared Blood Disorder Therapy - Bloomberg
August 17, 2022 1:54 PM EDTbluebird bio (NASDAQ: BLUE) to Charge $2.8M for Fda-Cleared Blood Disorder Therapy - Bloomberg
... MoreFDA Approves bluebird bio's (BLUE) Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions
August 17, 2022 1:40 PM EDTToday, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
"Today's approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing red blood cell transfusions," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "Given the potential health complications associated with this serious disease, this action highlights the FDA's continued commitment to supporting development of innovative therapies for patients who... More
bluebird bio (BLUE) Halted, News Pending
August 17, 2022 12:41 PM EDTbluebird bio (NASDAQ: BLUE) Halted, News Pending
... More